Rapid and scalable preclinical evaluation of personalized antisense oligonucleotide therapeutics using organoids derived from rare disease patients
John C. Means, Daniel A. Louiselle, Emily G. Farrow, Tomi Pastinen, Scott T. Younger
doi: https://doi.org/10.1101/2023.03.28.23287871
John C. Means
1Genomic Medicine Center, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
2Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
Daniel A. Louiselle
1Genomic Medicine Center, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
2Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
Emily G. Farrow
1Genomic Medicine Center, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
2Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
3Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO 64110, USA
Tomi Pastinen
1Genomic Medicine Center, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
2Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
3Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO 64110, USA
4Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160, USA
Scott T. Younger
1Genomic Medicine Center, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
2Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City, MO 64108, USA
3Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO 64110, USA
4Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160, USA
Data Availability
All data produced in the present work are contained in the manuscript
Posted March 29, 2023.
Rapid and scalable preclinical evaluation of personalized antisense oligonucleotide therapeutics using organoids derived from rare disease patients
John C. Means, Daniel A. Louiselle, Emily G. Farrow, Tomi Pastinen, Scott T. Younger
medRxiv 2023.03.28.23287871; doi: https://doi.org/10.1101/2023.03.28.23287871
Rapid and scalable preclinical evaluation of personalized antisense oligonucleotide therapeutics using organoids derived from rare disease patients
John C. Means, Daniel A. Louiselle, Emily G. Farrow, Tomi Pastinen, Scott T. Younger
medRxiv 2023.03.28.23287871; doi: https://doi.org/10.1101/2023.03.28.23287871
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2257)
- Dermatology (201)
- Emergency Medicine (368)
- Epidemiology (11549)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3541)
- Geriatric Medicine (336)
- Health Economics (612)
- Health Informatics (2287)
- Health Policy (910)
- Hematology (333)
- HIV/AIDS (742)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3326)
- Nursing (190)
- Nutrition (504)
- Oncology (1748)
- Ophthalmology (522)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (222)
- Palliative Medicine (66)
- Pathology (435)
- Pediatrics (998)
- Primary Care Research (399)
- Public and Global Health (5974)
- Radiology and Imaging (1216)
- Respiratory Medicine (807)
- Rheumatology (367)
- Sports Medicine (311)
- Surgery (383)
- Toxicology (50)
- Transplantation (170)
- Urology (142)